40 Hz gamma stimulation uses light flickering and sound pulsing 40 times a second to entrain brain rhythms. In MIT mouse studies it reduced amyloid and improved memory, possibly by boosting glymphatic clearance. But an independent group found no gamma entrainment or amyloid reduction in its replication. In people, small trials reported less brain shrinkage and slower loss of daily function on secondary measures while missing their main outcomes, and the 673-person HOPE trial finished in August 2026 with results still pending.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does 40 Hz stimulation clear amyloid?
In mice, MIT researchers reported that 40 Hz light flicker reduced amyloid (Iaccarino et al., Nature 2016) and that the effect works through glymphatic clearance (Murdock et al., Nature 2024). An independent lab did not reproduce the gamma entrainment or amyloid effect (Soula et al., Nature Neuroscience 2023).123
Has it been tested in people?
In small trials. The OVERTURE trial in 76 people with mild to moderate Alzheimer's missed its primary outcomes; daily living, MMSE and whole-brain volume declined less than with sham, at nominal significance only (Hajós et al., 2024).55
When will the big trial report?
The HOPE pivotal trial of 673 participants (NCT05637801) completed in August 2026. No results had been published as of October 2026.6
Is it safe?
The trials report it as well tolerated. Flashing light at these frequencies falls in the range considered a seizure hazard for people with photosensitive epilepsy (Harding et al., 2005).7
Gamma oscillations are fast brain rhythms, in the range of about 30 to 50 Hz, that are weakened in Alzheimer's disease. In 2016 the Tsai lab at MIT showed that flickering light at 40 Hz could drive these rhythms in mice and reduce amyloid. That launched a non-drug approach to Alzheimer's: an at-home headset that delivers synchronized 40 Hz light and sound in regular sessions. A 673-person pivotal trial (HOPE) finished in August 2026 and its results have not yet been published. Until they are, the human evidence rests on small trials with mixed results, and one independent mouse study failed to reproduce the original effect.
02The mouse evidence, for and against
- Original finding (Iaccarino et al., Nature 2016): driving fast-spiking interneurons at 40 Hz, and then simple 40 Hz light flicker, reduced amyloid-β in the visual cortex of Alzheimer's model mice and recruited microglia to plaques (PMID 27929004).
- Proposed mechanism (Murdock et al., Nature 2024): combined 40 Hz light and sound increased cerebrospinal-fluid flow through the brain's glymphatic clearance system; blocking that system abolished the amyloid reduction (PMID 38418876).
- Failed replication (Soula et al., Nature Neuroscience 2023): an independent group recording directly from visual cortex, entorhinal cortex and hippocampus found that 40 Hz flicker did not engage native gamma oscillations, produced no reliable change in plaques, microglia or amyloid-β levels, and that mice avoided the light (PMID 36879142).
03Human trials
| Trial | Design | Result |
|---|---|---|
| MIT feasibility and pilot, PLoS One 2022 | Phase 1 single session; phase 2A, 15 patients with mild Alzheimer's, 3 months, sham-controlled | Safe; induced 40 Hz entrainment including in deep structures (intracranial recordings in 2 epilepsy patients); active group had less ventricular enlargement and hippocampal atrophy and better face-name recall (PMID 36454969) |
| OVERTURE, Frontiers in Neurology 2024 | 76 patients with mild-to-moderate Alzheimer's, 6 months, 2:1 active vs sham | Missed its efficacy outcomes: no separation on the primary composite (MADCOMS), CDR-SB or ADAS-Cog14. Activities of daily living, MMSE and whole-brain volume declined less on active treatment, at nominal significance only. Safe, with 85-90% adherence (PMID 38515445) |
| HOPE pivotal (NCT05637801) | 673 patients, mild-to-moderate Alzheimer's, 12 months, sham-controlled, 70 US sites | Completed August 2026; no results posted as of mid-October 2026. Primary endpoint is a composite of MMSE and activities of daily living |
Swipe table →
Two things to note about OVERTURE. First, the company that makes the device ran the trial and most authors are its employees (disclosed). Second, HOPE's primary endpoint combines the two measures (MMSE and daily living) that happened to move in OVERTURE after its registered primary missed. That is a legitimate design choice, but it means HOPE is the real test, not a confirmation.
04Consumer devices are not the trial device
The trial systems are medical devices that deliver calibrated, synchronized light and sound and, in OVERTURE, EEG-verified gamma responses. Flicker apps, lamps and videos sold as "40 Hz therapy" have not been tested in any of these trials. 40 Hz flicker can be uncomfortable, and an expert consensus on photosensitive epilepsy treats bright flashes at 3 Hz or faster as a potential seizure hazard, a range that includes 40 Hz (PMID 16146438).
05Where it sits on the Heretic scale
Early. A strong but contested mouse literature, a small positive pilot, and a feasibility RCT that missed its efficacy outcomes with nominal secondary signals. The HOPE readout will move this entry either way: a clean positive result on its primary endpoint would justify Promising. Related: Red light therapy, Electromagnetic therapies, Sleep optimization (glymphatic clearance happens mostly during sleep), Low-dose lithium and Shingles vaccination and dementia.
What studies and practitioners report
Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.
- Trial 1 hour/day · 40 Hz audiovisual stimulation at home, 6 months adults with mild to moderate Alzheimer's, OVERTURE PMID 38515445
Further reading: detailed protocols
- ClinicalTrials.gov: HOPE pivotal trial (NCT05637801) clinicaltrials.gov
- ClinicalTrials.gov: OVERTURE trial (NCT03556280) clinicaltrials.gov
06Connections
07Sources
- Iaccarino HF, et al. (2016). "Gamma frequency entrainment attenuates amyloid load and modifies microglia." Nature 540(7632):230-235. PMID 27929004 . DOI 10.1038/nature20587PubMed 27929004 · DOI 10.1038/nature20587
- Murdock MH, et al. (2024). "Multisensory gamma stimulation promotes glymphatic clearance of amyloid." Nature 627(8002):149-156. PMID 38418876 . DOI 10.1038/s41586-024-07132-6PubMed 38418876 · DOI 10.1038/s41586-024-07132-6
- Soula M, et al. (2023). "Forty-hertz light stimulation does not entrain native gamma oscillations in Alzheimer's disease model mice." Nat Neurosci 26(4):570-578. PMID 36879142 . DOI 10.1038/s41593-023-01270-2PubMed 36879142 · DOI 10.1038/s41593-023-01270-2
- Chan D, et al. (2022). "Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies." PLoS One 17(12):e0278412. PMID 36454969 . DOI 10.1371/journal.pone.0278412PubMed 36454969 · DOI 10.1371/journal.pone.0278412
- Hajós M, et al. (2024). "Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer's disease." Front Neurol 15:1343588. PMID 38515445 . DOI 10.3389/fneur.2024.1343588 . Trial NCT03556280PubMed 38515445 · DOI 10.3389/fneur.2024.1343588 · NCT03556280
- HOPE pivotal study of sensory stimulation in Alzheimer's disease. ClinicalTrials.gov NCT05637801NCT05637801
- Harding G, et al. (2005). "Photic- and pattern-induced seizures: expert consensus of the Epilepsy Foundation of America Working Group." Epilepsia . PMID 16146438 . DOI 10.1111/j.1528-1167.2005.31305.xPubMed 16146438 · DOI 10.1111/j.1528-1167.2005.31305.x
08Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.